Oct 3 (Reuters) - Bubs Australia (BUB) on Monday said that it had lodged a letter of intent with the U.S. Food and Drug Administration (FDA) for permanent market access in the United States to October 2025 and beyond.
The infant formula maker said the FDA intends to issue a letter of acknowledgement in response to the letter of intent.
News: BUB Bubs Australia seeks permanent market access from U.S. FDA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $151.8M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $91.61K | 522.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 1899644 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 57813 | 3 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| BUB (ASX) Chart |